Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching HIV-positive women with undetectable viremia from tenofovir/emtricitabine + boosted atazanavir to raltegravir + boosted atazanavir: effects on bone mineral density
2013-002349-12Phase 4Active
- Sponsor
- University of Turin
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of raltegravir, atazanavir, ritonavir, tenofovir and emtricitabine in human immunodeficiency virus infection (HIV) and osteopenia (2 arms), sponsored by University of Turin. Primary endpoints: Change in spine bone mineral density at 48 weeks and Change in femur bone mineral density at 48 weeks. Started Jun 2013; status: active.
02
Drugs
raltegraviratazanavirritonavirtenofoviremtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)osteopenia
Beyond the preview
Go deeper on 2013-002349-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002349-12.